Skip to content
LexBuild

Agency Information Collection Activities: Proposed Collection; Comment Request

---
identifier: "/us/fr/2022-22844"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Agency Information Collection Activities: Proposed Collection; Comment Request"
title_number: 0
title_name: "Federal Register"
section_number: "2022-22844"
section_name: "Agency Information Collection Activities: Proposed Collection; Comment Request"
positive_law: false
currency: "2022-10-21"
last_updated: "2022-10-21"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2022-22844"
document_type: "notice"
publication_date: "2022-10-21"
agencies:
  - "Health and Human Services Department"
  - "Centers for Medicare & Medicaid Services"
fr_citation: "87 FR 64052"
fr_volume: 87
docket_ids:
  - "Document Identifier: CMS-10260"
comments_close_date: "2022-12-05"
fr_action: "Notice; partial withdrawal."
---

#  Agency Information Collection Activities: Proposed Collection; Comment Request

**AGENCY:**

Centers for Medicare & Medicaid Services, HHS.

**ACTION:**

Notice; partial withdrawal.

**SUMMARY:**

On Wednesday, October 5, 2022, the Centers for Medicare & Medicaid Services (CMS) published a notice document entitled, “Agency Information Collection Activities: Proposed Collection; Comment Request”. That notice invited public comments on two separate information collection requests, under Document Identifiers: CMS-10260 and CMS-10142. Through the publication of this document, we are withdrawing the portion of the notice requesting public comment on the information collection request titled, ” Medicare Advantage and Prescription Drug Program: Final Marketing Provisions.” Form number: CMS-10260 (OMB control number: 0938-1051).

**DATES:**

The original comment period for the document that published on October 5, 2022, remains in effect and ends December 5, 2022.

**SUPPLEMENTARY INFORMATION:**

In FR document, 2022-21657, published on October 5, 2022 (87 FR 60403), we are withdrawing item 1 “Medicare Advantage and Prescription Drug Program: Final Marketing Provisions in 42 CFR 422.111(a)(3) and 423.128(a)(3)” which begins on page 60404. The notice will be republished at a later date, thereby allowing the public to have a full 60-day comment period.

Dated: October 17, 2022.

William N. Parham, III,

Director, Paperwork Reduction Staff, Office of Strategic Operations and Regulatory Affairs.